Thank you for Subscribing to Life Science Review Weekly Brief
×
Life Science Review Weekly Brief
Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review
Giuliano to Lead Finance-Related Leadership Functions as New CFO at Aeterna
Life Sciences Review
Life Sciences Review | Friday, January 21, 2022
Mr. La Fratta will take over the finance-related leadership roles as the new Senior Vice President and Chief Financial Officer of Aeterna Zentaris.
Fremont, CA: Dr. Klaus Paulini, Chief Executive Officer of Aeterna, comments, "We are very pleased to welcome Mr. La Fratta as our full-time Chief Financial Officer." Aeterna Zentaris Inc. has appointed Giuliano La Fratta as Senior Vice President, Chief Financial Officer. Aeterna Zentaris Inc. is a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products. Mr. La Fratta will take over the finance-related leadership roles on January 24th, 2022, succeeding Ms. Leslie Auld, the Company's current Senior Vice President and Chief Financial Officer, who will focus on her financial consulting practice.
Mr. La Fratta is a senior financial executive with more than 20 years of expertise in the pharmaceutical, biopharmaceutical, and financial services industries. He has worked in both the public and private sectors, gaining valuable experience in leading and directing a wide range of financial activities, including mergers and acquisitions, corporate development, auditing, accounting, and administrative responsibilities.
Mr. La Fratta was the Vice President of Finance at CellCarta (previously Caprion Biosciences), a private equity-owned specialty Clinical Research and Development Organization laboratory with global operations located in Montreal, Canada, prior to joining Aeterna Zentaris.
Mr. La Fratta worked at IMS Canada Health (now Iqvia) and Cato Research before joining CellCarta. He began his career as a Senior Auditor at Deloitte Touche, working for both Canadian and American corporations in a variety of industries, including the pharmaceutical industry. Mr. La Fratta graduated from Concordia University with a bachelor's degree in accounting and is a CPA, CA.
“Aeterna has had a transformational year as a company. The team has done a great job to strengthen the financial position of the Company and to diversify Aeterna's development pipeline. Looking ahead, there are significant opportunities and key markets that I believe Aeterna is poised to address. I look forward to working with the team to capitalize on the opportunities ahead, with the goal of building value in the near and long term,” comments Mr. La Fratta.
Data Science In R&D: It Is About Culture
Philippe MARC, Executive Director, Global Head of Integrated Data Science, Novartis
Partnering With A Cdmo For Successful Late Phase Biologic Drug Product Development And Launch
Roman Mathaes, Head of Pharmaceutical Services and Cristina GrigoreCristina Grigore, at Lonza
Leading Global Cdmo, Pci Has Further Expanded Its European Biotech Packaging Capabilities With Investment Across Europe In Both The Uk And Ireland Facilities
Chris Dobbs, CEng., MIET, Head of Technical Engineering, PCI Pharma Services
Encouraging Innovation in Healthcare in a COVID - 19 World
Duncan Turner, General Partner, SOSV, Managing Director, HAX
How Allogeneic Stem Cell Therapies Can Transform Prospects In Inherited Retinal Diseases
Gil Carrasquinho, VP Head of Cell Therapy, Santen
Optimizing Clinical Trials: Leveraging Technology To Improve Drug Development
Craig Herron, Managing Director, iSelect Fund
Addressing the Expanded Role of Patient Engagement in Clinical Research
Denis Curtin, PhD, Principal, eCOA & Patient Engagement, Signant Health
The Future of Imaging and the Role of the Pathology Data Scientist in Drug Discovery
Jason Hipp, Senior Director, Head of Pathology Data Science & Innovation, Translational, AstraZeneca
